Rral-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C GT1 in Germany – an interim analysis

Background/aims: Telaprevir (TVR)-based triple therapy in patients (pts) with chronic Hepatitis C (HCV) in daily practice in Germany is investigated in this non-interventional study to evaluate the implementation of futility rules, response-guided therapy, safety and efficiency. Methods: Prospective study, investigating TVR-based therapy in therapy-naive and pretreated pts with chronic HCV GT 1. Data from the first 400 pts starting treatment (50% of the planned total) at 67 sites, followed up for a maximum of 24 weeks (W) of treatment. Results: 70.3% of pts were pretreated (41.3% prior relapser, 32.7% non-respon…